T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-04: Form 8-K; Period of report 2016-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-11-03: Form 8-K; Period of report 2016-11-01; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2016-09-22: Form 8-K; Period of report 2016-09-21; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 1.01.
- 2016-09-07: Form 8-K; Period of report 2016-08-31; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-04 | 8-K | 2016-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2016, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended September 30, 2016 and held a conference call to discuss those results. | a16-20704_28k.htm |
| 2016-11-03 | 8-K | 2016-11-01 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On November 1, 2016, the Company issued a press release announcing the Company’s entry into the Agreement. | a16-20704_18k.htm |
| 2016-09-22 | 8-K | 2016-09-21 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 As described in Item 1.01 of this Current Report on Form 8-K, which is incorporated in this Item 3.02 by reference, the Company sold an aggregate of 6,055,341 shares of Common Stock to Canon pursuant to the Purchase Agreement. 5.02 Under the terms of the Voting and Standstill Agreement, the Board elected Seymour Liebman, Executive Vice President, Chief Administrative Officer and General Counsel of Canon, as a director, effective on September 21, 2016, filling an existing vacancy on the Board. 7.01 On September 22, 2016, the Company issued a press release regarding the Agreements and Mr. Liebman’s election to the Board. | a16-18840_18k.htm |
| 2016-09-07 | 8-K | 2016-08-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 31, 2016, T2 Biosystems, Inc. (the “Company”) received a written letter of resignation from Harry Wilcox stating that he resigned, effective immediately, from his position as a Class I director of the Company and all committees of the Board of Directors of the Company (the “Board”) on which he was serving. | a16-18065_18k.htm |
| 2016-08-03 | 8-K | 2016-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2016, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2016 and held a conference call to discuss those results. | a16-16041_18k.htm |
| 2016-07-07 | 8-K | 2016-07-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 5.02 (c) On July 6, 2016, the Board of Directors (the “Board”) of T2 Biosystems, Inc. (the “Company”) appointed Dr. Joanne Spadoro, Ph. 7.01 On July 7, 2016, T2 Biosystems, Inc. (the “Company”) issued a press release in connection with the announcements discussed in Item 5.02 above and Item 8.01 below. 8.01 On July 7, 2016, the Company announced its plans to initiate a voluntary recall and replacement of its T2Candida cartridges at certain customer sites. | a16-14599_18k.htm |
| 2016-06-22 | 8-K | 2016-06-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 (a) The Annual Meeting of Stockholders of T2 Biosystems, Inc. (the “Company”) occurred on June 17, 2016. | a16-13761_18k.htm |
| 2016-05-25 | 8-K | 2016-05-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On May 20, 2016, Sarah Kalil resigned as Chief Operating Officer of T2 Biosystems, Inc. She will continue to be employed by the Company. | a16-12060_18k.htm |
| 2016-05-04 | 8-K | 2016-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2016, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2016 and held a conference call to discuss those results. | a16-10502_28k.htm |
| 2016-05-04 | 8-K | 2016-04-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On April 28, 2016, Moe Castonguay notified T2 Biosystems, Inc. (the “Company”) of his retirement from his position as the Company’s Chief Financial Officer effective immediately following the Company’s filing with the Securities and Exchange Commission of its quarterly report on Form 10-Q for the quarter ending March 31, 2016 and as an employee effective June 30, 2016. | a16-10502_18k.htm |
| 2016-04-15 | 8-K | 2016-04-11 | 2.02 Results of Operations and Financial Condition | 2.02 On April 11, 2016, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary financial results for the first fiscal quarter of 2016 and held a conference call to discuss those results. | a16-8368_18k.htm |
| 2016-03-15 | 8-K | 2016-03-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 9, 2016, T2 Biosystems, Inc. (the “Company”) received a written letter of resignation from Thomas J. Carella stating that he resigned, effective immediately, from his position as a Class II director of the Company and all committees of the Board of Directors of the Company (the “Board”) on which he was serving. | a16-6258_18k.htm |
| 2016-02-18 | 8-K | 2016-02-16 | 2.02 Results of Operations and Financial Condition | 2.02 On February 16, 2016, T2 Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter and fiscal year ended December 31, 2015 and held a conference call to discuss those results. | a16-4744_18k.htm |